Evidence map›Paper›PMID 38033034›Full record

ArticlePloS one2023

TK1 expression influences pathogenicity by cell cycle progression, cellular migration, and cellular survival in HCC 1806 breast cancer cells.

Eliza E Bitter, Jonathan Skidmore, Carolyn I Allen, Rachel I Erickson, Rachel M Morris, Toni Mortimer, Audrey Meade, Rachel Brog, Tim Phares, Michelle Townsend and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Eliza E BitterDepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, Utah, United States of America.ORCID 0000-0001-5339-2544
Jonathan SkidmoreDepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, Utah, United States of America.ORCID 0000-0001-5488-5412
Carolyn I AllenDepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, Utah, United States of America.
Rachel I EricksonDepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, Utah, United States of America.ORCID 0000-0001-8857-4583
Rachel M MorrisDepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, Utah, United States of America.
Toni MortimerDepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, Utah, United States of America.
Audrey MeadeThunder Biotech Inc., Provo, Utah, United States of America.
Rachel BrogThunder Biotech Inc., Provo, Utah, United States of America.
Tim PharesThunder Biotech Inc., Provo, Utah, United States of America.
Michelle TownsendDepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, Utah, United States of America.
Brett E PickettDepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, Utah, United States of America.
Kim L O'NeillDepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, Utah, United States of America.ORCID 0000-0002-8747-6217
Brigham Young University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the most common cancer diagnosis worldwide accounting for 1 out of every 8 cancer diagnoses. The elevated expression of Thymidine Kinase 1 (TK1) is associated with more aggressive tumor grades, including breast cancer. Recent studies indicate that TK1 may be involved in cancer pathogenesis; however, its direct involvement in breast cancer has not been identified. Here, we evaluate potential pathogenic effects of elevated TK1 expression by comparing HCC 1806 to HCC 1806 TK1-knockdown cancer cells (L133). Transcriptomic profiles of HCC 1806 and L133 cells showed cell cycle progression, apoptosis, and invasion as potential pathogenic pathways affected by TK1 expression. Subsequent in-vitro studies confirmed differences between HCC 1806 and L133 cells in cell cycle phase progression, cell survival, and cell migration. Expression comparison of several factors involved in these pathogenic pathways between HCC 1806 and L133 cells identified p21 and AKT3 transcripts were significantly affected by TK1 expression. Creation of a protein-protein interaction map of TK1 and the pathogenic factors we evaluated predict that the majority of factors evaluated either directly or indirectly interact with TK1. Our findings argue that TK1 elevation directly increases HCC 1806 cell pathogenicity and is likely occurring by p21- and AKT3-mediated mechanisms to promote cell cycle arrest, cellular migration, and cellular survival.

Indexed as

Breast NeoplasmsCarcinoma, HepatocellularLiver NeoplasmsCell DivisionCell MovementCell SurvivalFemaleHumansThymidine KinaseVirulenceThymidine Kinasethymidine kinase 1

Identifiers

PMID38033034
PMCPMC10688958
OpenAlexW4389166202

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.